Sofosbuvir/ledipasvir fixed-dose combination for treatment of chronic hepatitis C virus infection in children

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

The United States Food and Drug Administration recently approved sofosbuvir and the fixed-dose combination of ledipasvir/sofosbuvir for the treatment of hepatitis C virus (HCV) infection in children ages 12 to 17. These are the first direct-acting antiviral treatments approved for children and adolescents with HCV. Pharmacokinetic data confirm equivalent drug exposure in this population as that found in adults during clinical trials. The efficacy and safety of these drugs has been shown in clinical trials.

Original languageEnglish (US)
Pages (from-to)447-451
Number of pages5
JournalDrugs of Today
Volume53
Issue number8
DOIs
StatePublished - Aug 1 2017

Fingerprint

Chronic Hepatitis C
Virus Diseases
Hepacivirus
Clinical Trials
United States Food and Drug Administration
Pharmaceutical Preparations
Antiviral Agents
Pharmacokinetics
Safety
Therapeutics
Population
sofosbuvir drug combination ledipasvir
Sofosbuvir

Keywords

  • Children
  • Hepatitis C
  • Ledipasvir/sofosbuvir

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this

Sofosbuvir/ledipasvir fixed-dose combination for treatment of chronic hepatitis C virus infection in children. / Rizza, Stacey; Nehra, V.; Temesgen, Zelalem.

In: Drugs of Today, Vol. 53, No. 8, 01.08.2017, p. 447-451.

Research output: Contribution to journalArticle

@article{980ce9290d9e4a9d96599c00e0a5fd4d,
title = "Sofosbuvir/ledipasvir fixed-dose combination for treatment of chronic hepatitis C virus infection in children",
abstract = "The United States Food and Drug Administration recently approved sofosbuvir and the fixed-dose combination of ledipasvir/sofosbuvir for the treatment of hepatitis C virus (HCV) infection in children ages 12 to 17. These are the first direct-acting antiviral treatments approved for children and adolescents with HCV. Pharmacokinetic data confirm equivalent drug exposure in this population as that found in adults during clinical trials. The efficacy and safety of these drugs has been shown in clinical trials.",
keywords = "Children, Hepatitis C, Ledipasvir/sofosbuvir",
author = "Stacey Rizza and V. Nehra and Zelalem Temesgen",
year = "2017",
month = "8",
day = "1",
doi = "10.1358/dot.2017.53.8.2687529",
language = "English (US)",
volume = "53",
pages = "447--451",
journal = "Drugs of Today",
issn = "1699-3993",
publisher = "Prous Science",
number = "8",

}

TY - JOUR

T1 - Sofosbuvir/ledipasvir fixed-dose combination for treatment of chronic hepatitis C virus infection in children

AU - Rizza, Stacey

AU - Nehra, V.

AU - Temesgen, Zelalem

PY - 2017/8/1

Y1 - 2017/8/1

N2 - The United States Food and Drug Administration recently approved sofosbuvir and the fixed-dose combination of ledipasvir/sofosbuvir for the treatment of hepatitis C virus (HCV) infection in children ages 12 to 17. These are the first direct-acting antiviral treatments approved for children and adolescents with HCV. Pharmacokinetic data confirm equivalent drug exposure in this population as that found in adults during clinical trials. The efficacy and safety of these drugs has been shown in clinical trials.

AB - The United States Food and Drug Administration recently approved sofosbuvir and the fixed-dose combination of ledipasvir/sofosbuvir for the treatment of hepatitis C virus (HCV) infection in children ages 12 to 17. These are the first direct-acting antiviral treatments approved for children and adolescents with HCV. Pharmacokinetic data confirm equivalent drug exposure in this population as that found in adults during clinical trials. The efficacy and safety of these drugs has been shown in clinical trials.

KW - Children

KW - Hepatitis C

KW - Ledipasvir/sofosbuvir

UR - http://www.scopus.com/inward/record.url?scp=85032932709&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85032932709&partnerID=8YFLogxK

U2 - 10.1358/dot.2017.53.8.2687529

DO - 10.1358/dot.2017.53.8.2687529

M3 - Article

C2 - 29119149

AN - SCOPUS:85032932709

VL - 53

SP - 447

EP - 451

JO - Drugs of Today

JF - Drugs of Today

SN - 1699-3993

IS - 8

ER -